Hydroxymethylquinoxalindioxyde

Phase 3Small molecule

VValenta Pharm JSC

Hydroxymethylquinoxalindioxyde is one of 9 small molecule programs targeting Pyoderma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PyodermaActive, not recruiting

PyodermaPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Pyoderma

#DrugCompanyPhaseTrials

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—2

Tygacil

PPrism Pharmaceuticals

Humira

Velsipity

Taltz

Cosentyx

Ilaris

Spevigo

Hydroxymethylquinoxalindioxyde

VValenta Pharm JSC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Infusion1 trial

Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

Completed·VValenta Pharm JSC·Phase 1·NCT05505097·16 enrolled

Pyoderma1 trial

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Completed·VValenta Pharm JSC·Phase 3·NCT05561816·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hydroxymethylquinoxalindioxyde. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydroxymethylquinoxalindioxyde compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydroxymethylquinoxalindioxyde. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valenta Pharm JSC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VValenta Pharm JSC

Hydroxymethylquinoxalindioxyde

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Infusion1 trial

Pyoderma1 trial

References

Drug Info

Quick Facts

Related News